Emerging trends in hepatocellular carcinoma: Focus on diagnosis and therapeutics

Clinical Medicine Insights: Oncology

Volumn 8, Issue , 2014, Pages 71-76

  Flores, Avegail ^a   Marrero, Jorge A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Alpha fetoprotein (AFP); Dynamic imaging; Hepatocellular carcinoma (HCC); Liver transplantation; Molecular targets; Radiofrequency ablation (RFA); Sorafenib; Trans arterial chemoembolization (TACE); Ultrasound; Yttrium 90 (Y 90) radioembolization

Indexed keywords

AXITINIB; BELINOSTAT; BEVACIZUMAB; BILIRUBIN; CABOZANTINIB; CEDIRANIB; CETUXIMAB; DOXORUBICIN; EVEROLIMUS; GADOLINIUM PENTETATE; GADOXETIC ACID; GANETESPIB; GEFITINIB; LAPATINIB; LENALIDOMIDE; LENVATINIB; LINIFANIB; PAZOPANIB; RAMUCIRUMAB; RAPAMYCIN; SORAFENIB; TEMSIROLIMUS; TIVANTINIB; YTTRIUM 90;

ADVANCED CANCER; ARTICLE; ARTIFICIAL EMBOLISM; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CONTRAST ENHANCEMENT; DIARRHEA; FATIGUE; HAND FOOT SYNDROME; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MULTIDETECTOR COMPUTED TOMOGRAPHY; NAUSEA AND VOMITING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIOFREQUENCY ABLATION; SIDE EFFECT; SKIN MANIFESTATION; VIRUS CARRIER; WEIGHT REDUCTION;

EID: 84901241878     PISSN: None     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S9926     Document Type: Article

References (57)

1. IARC. Liver Cancer: Estimated Incidence, Mortality, Prevalence Worldwide in 2012. http://globocaniarcfr/Pages/fact_sheets_canceraspx. 2012. Accessed December 12, 2013.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
4. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(suppl 19):102-7.
5. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-27.
6. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst. 1980;64:1263-72.
7. Yang B, Zhang B, Xu Y, etal. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol. 1997;123:357-60.
8. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-22.
9. Lok AS, Sterling RK, Everhart JE, etal. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493-502.
10. Singal A, Volk ML, Waljee A, etal. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47.
11. Singal AG, Conjeevaram HS, Volk ML, etal. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793-9.
12. Kudo M, Izumi N, Kokudo N, etal. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339-64.
13. Sterling RK, Jeffers L, Gordon F, etal. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol. 2007;102:2196-205.
14. Marrero JA, Su GL, Wei W, etal. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003;37:1114-21.
15. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl. 2005;11:281-9.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-2.
17. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis. 2010;30:17-25.
18. Forner A, Vilana R, Ayuso C, etal. Diagnosis of hepatic nodules 20mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97-104.
19. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-43.
20. Halavaara J, Breuer J, Ayuso C, etal. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT-a multicenter trial. J Comput Assist Tomogr. 2006;30:345-54.
21. Lee MH, Kim SH, Park MJ, Park CK, Rhim H. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol. 2011;197:W868-75.
22. Park MJ, Kim YK, Lee MW, etal. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology. 2012;264:761-70.
23. Inoue T, Kudo M, Komuta M, etal. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol. 2012;47:1036-47.
24. Marrero JA, Fontana RJ, Barrat A, etal. Prognosis of hepatocellular carcinoma: comparison of 7staging systems in an American cohort. Hepatology. 2005;41:707-16.
25. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181-200.
26. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-40.
27. Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg. 2012;99:1622-9.
28. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003;197:753-8.
29. Mazzaferro V, Regalia E, Doci R, etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9.
30. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma, or = 4 cm. Gastroenterology. 2004;127:1714-23.
31. Shiina S, Teratani T, Obi S, etal. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122-30.
32. Livraghi T, Meloni F, Di Stasi M, etal. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008;47:82-9.
33. Lo CM, Ngan H, Tso WK, etal. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-71.
34. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-42.
35. Yao FY, Kerlan RK Jr, Hirose R, etal. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48:819-27.
36. Varela M, Real MI, Burrel M, etal. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474-81.
37. Lammer J, Malagari K, Vogl T, etal. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52.
38. Malagari K, Pomoni M, Kelekis A, etal. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33:541-51.
39. Cheng JC, Wu JK, Huang CM, etal. Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol. 2002;63:41-5.
40. Salem R, Lewandowski RJ, Mulcahy MF, etal. Radioembolization for hepatocellular carcinoma using Yttrium-90microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52-64.
41. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129-40.
42. Llovet JM, Ricci S, Mazzaferro V, etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
43. Cheng AL, Kang YK, Chen Z, etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
44. Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract. 2010;64:1034-41.
45. Lencioni R, Llovet JM, Han G, etal. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SAPCE trial. J Clin Oncol. 2012;30.
46. Kudo M, Imanaka K, Chida N, etal. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117-27.
47. Kudo M. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology. 2011;81(Suppl 1):50-5.
48. Mendel DB, Laird AD, Xin X, etal. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Res. 2003;9:327-37.
49. Cheng AL, Kang YK, Lin D, etal. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011;29.
50. Squib B-M. BRISK-FL study with investigational compound brivanib in hepatocellular carcinoma does not meet overall survival primary endpoint. 2012, in press. http://news.bms.com/press-release/rd-news/brisk-fl-studyinvestigational-compound-brivanib-hepatocellular-carcinoma-does.
51. Abou-Alfa GK, Johnson P, Knox JJ, etal. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304:2154-60.
52. Zhang SZ, Pan FY, Xu JF, etal. Knockdown of c-MET by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther. 2005;4:1577-84.
53. Santoro A, Rimassa L, Borbath I, etal. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14:55-63.
54. Cohn A, Kelley, RK, Yang TS, etal. Activity of cabozantinib (XL184) in hepatocellular carcinoma patients: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30(suppl 4).
55. Zhu AX, Finn RS, Mulcahy, MF etal. A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2010;28.
56. Villanueva A, Chiang DY, Newell P, etal. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972-83.
57. Novartis. Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival 2013. http://www.novartis.com/newsroom/media-releases/en/2013/1721562.shtml.